Metoprolol succinate extended release/hydrochlorothiazide combination tablets

Vascular Health and Risk Management

Volumn 3, Issue 3, 2007, Pages 279-288

  Hainer, James W ^a   Sugg, Jennifer ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antihypertensive; Blood pressure; Cardiovascular disease; Combination product

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTOPROL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS METOPROLOL SUCCINATE; METOPROLOL SUCCINATE; SELOCOMB ZOK; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; GENETIC HETEROGENEITY; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; STROKE; SUSTAINED RELEASE PREPARATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; METOPROLOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34547700948     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 288:2981-97.
2. Bakris GL, Fonseca V, Katholi RE, et al. 2004. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA, 292:2227-36.
3. Beermann B, Groschinsky-Grind M, Rosen A. 1976. Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol and Thera, 19:531-7.
4. Dahlof B, Lindholm LH, Hansson L, et al. 1991. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet, 338:1281-5.
5. Darmansjah I, Wong E, Setiawati A, et al. 1990. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. J Clin Pharmacol, 30:S39-S45.
6. Dornhorst A, Powell SH, Pensky J. 1985. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet, 1:123-6.
7. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. 2003. J Hypertension, 21:1011-53.
8. Falkner B, Francos G, Kushner H. 2006. Metoprolol succinate, a selective β-adrenergic blocker, has no effect on insulin sensitivity. J Clin Hypertension, 8:336-43.
9. Geisler LS. 1981. Hypertension therapy in the elderly. MedWelt, 32:910-14.
10. Goodfellow R, Westberg B. 1981. The treatment of high blood pressure in the elderly: a multi-center evaluation of a fixed combination of metoprolol and hydrochlorothiazide (Co-Betaloc) in general practice. Curr Med Res Opin, 7:536-42.
11. Gu Q, Paulose-Ram R, Dillon C, Burt V. 2006. Antihypertensive medication use among US adults with hypertension. Circulation, 113:213-21.
12. Hajjar I, Kotchen T. 2003. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA, 290:199-206.
13. Hansson L, Lindholm LH, Ekbom T, et al. 1999. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet, 354:1751-6.
14. Hawkins DW, Dieckmann MR, Horner RD. 1988. Diuretics and hypertension in black adults. Arch Intern Med, 148:803-5.
15. Hildemann SK, Fischer H, Pittrow D, et al. 2002. Metoprolol succinate SR plus hydrochlorothiazide (Beloc-Zok® Comp) in patients with essential hypertension in general practice. A prospective, observational trial in 14,964 patients. Clin Drug Invest, 22:719-29.
16. Holland OB, Fairchild C. 1982. Renin classification for diuretic and beta-blocker treatment of black and hypertensive patients. J Chron Dis, 35:179-82.
17. HydroDiuril® (hydrochlorothiazide) professional information brochure. 1998. Merck & Co., Inc.
18. JNC 7 report; Chobanian AV, Bakris GL, Black HR, et al. 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA, 289:2560-71.
19. Jordo L, Johnsson G, Lundborg P, et al. 1979. Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide. Br J Clin Pharmacol, 7:563-7.
20. Julius S, Nesbitt SD, Eagan BM, et al. 2006. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med, 354: 1685-97.
21. LaPalio L, Schork A, Glasser S, et al. 1992. Safety and efficacy of metoprolol in the treatment of hypertension in the elderly. J Am Geriatr Soc, 40:354-8.
22. Mourad J-J, Waeber B, Zannad F, et al on behalf of the investigators of the STRATHE trial. 2004. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. Journal of Hypertension, 22:2379-86.
23. Ofili E. 2006. Dispelling the myth of "aggressive" antihypertensive therapy. J Clin Hypertens, 8(Suppl 1):4-11.
24. Papademetriou V, Hainer JW, Sugg J, et al, and ATTACH Study Group. 2006. Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination. Am J Hypertens, 19:1217-25.
25. Papademetriou V, Reif M, Henry D, et al. 2000. Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension. J Clin Hypertens, 2:372-8.
26. Plosker GL, Clissold SP. 1992. Controlled release metoprolol formulations: a review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs, 43:382-414.
27. Psaty BM, Lumley T, Furberg C, et al. 2003. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA, 289:2534-44.
28. Samuelsson O, Hedner T, Berglund G, et al. 1994. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the primary prevention trial Goteborg, Sweden. J Hum Hypertens, 8:257-63.
29. Sandberg A, Ragnarsson G, Jonsson UE, et al. 1988. Design of a new multiple-unit controlled-release formulation of metoprolol-metoprolol CR. Eur J Clin Pharmacol, 33:S3-S7.
30. Sandberg A, Abrahamsson B, Regârdh C-G, et al. 1990. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol, 30:S2-S16.
31. The Association of Black Cardiologists (ABC) Candesartan Study Group. 2000. Evaluation of candesartan cilexetil in black patients with systemic hypertension: The ABC Trial. Heart Dis, 2:392-9.
32. TOPROL-XL® (metoprolol succinate) Extended Release Tablets professional information brochure. 2005. AstraZeneca LP.
33. Turnbull F, Neal B, Algert C, et al. 2003. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 362:1527-35.
34. Wikstrand J, Westergren G., Berglund G, et al. 1986. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. JAMA, 255:1304-10.
35. [WHO] World Health Organization, International Society of Hypertension Writing Group. 2003. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens, 21:1983-92.